Abstract
Androgen deprivation therapy (ADT) has been considered for years the standard initial
treatment for patients with metastatic prostate cancer (mPC). Recently published results
support the use of taxanes, second-generation antiandrogens or radiotherapy to the
primary tumor as part of the treatment in these patients, considering ADT alone as
suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for
oligometastatic patients in different tumor types. In oligometastatic hormone-sensitive
prostate cancer the role of MDT is being studied with promising results. In the present
review we assess the available evidence for radiotherapy to the primary tumor in newly
diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions
in this clinical setting.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med. 2013; 368: 138-148
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med. 2014; 371: 424-433
- Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.N Engl J Med. 2017; 377: 352-360
- Enzalutamide with standard first-line therapy in metastatic prostate cancer.N Engl J Med. 2019; 381: 121-131
- A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.J Clin Oncol. 2019; 37: 2974-2986
- Apalutamide for metastatic, castration-sensitive prostate cancer.N Engl J Med. 2019; 381: 13-24
- Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis.J Urol. 2015; 194: 378-385
- The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis.Eur Urol. 2017; 72: 14-19
- Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial.Eur Urol. 2019; 75: 410-418
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet. 2018; 392: 2353-2366
NCCN clinical practice guidelines in oncology. [Internet]. Pennsylvania, EEUU: National Comprehensive Cancer Network (NCCN); 2020 [actualizado enero 2022; citado 17 marzo 2022]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.Eur Urol. 2021; 79: 263-282
- Oligometastases.J Clin Oncol. 1995; 13: 8-10
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.Lancet. 2019; 393: 2051-2058
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.N Engl J Med. 2015; 373: 737-746
- Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis.Eur Urol. 2019; 76: 115-124
U.S. National Library of Medicine. ClinicalTrial.gov [Internet] U.S. National Library of Medicine; [acces data 14 april 2022]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01957436.
- Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer. A secondary analysis of a randomized clinical trial.JAMA Oncol. 2021; 7: 555-563
- Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.J Clin Oncol. 2018; 36: 446-453
- Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-years results of a randomized phase II trial.J Clin Oncol. 2020; 38 (10-10)
- Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.JAMA Oncol. 2020; 6: 650-659
- Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials.J Clin Oncol. 2022; 40: 3377-3382
- Phase II trial of SBRT and androgen deprivation for oligometastases in prostate cancer.Int J Rad Oncol Biol Phys. 2021; 111: S59
- OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer.Eur Urol. 2021; 80: 405-414
- Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes.Clin Genitourin Cancer. 2017; 15: 623-632
- Recent advances in the management of hormone-sensitive oligometastatic prostate cancer.Cancer Manage Res. 2022; 14: 89-101
- Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness.Clin Genitourin Cancer. 2021; 19: 230-236
- Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial.Eur Urol. 2018; 74: 455-462
- Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. A meta-analysis.Am J Clin Oncol. 2020; 43: 73-81
- Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.Br J Radiol. 2020; 93: 1-9
- Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences.Clin Oncol R Coll Radiol G B. 2016; 28: 115-120
- Diagnostic performance of PET imaging using different radiopharmaceuticals in prostate cancer according to published meta-analyses.Cancers (Basel). 2020; 12: 2153
- The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited.Eur Urol. 2021; 80: 632-640
- Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer.Int J Radiat Oncol Biol Phys. 2021; 109: 387-395
U.S. National Library of Medicine. ClinicalTrial.gov [Internet] U.S. National Library of Medicine; [citado 20 de mar de 2022]. Disponible en: https://clinicaltrials.gov
- Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.Radiat Oncol. 2014; 9: 135
- Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only.Strahlenther Onkol. 2015; 191: 310-320
- The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases.Eur Urol Focus. 2021; 7: 241-244
Article info
Publication history
Published online: November 10, 2022
Accepted:
October 29,
2022
Received in revised form:
October 25,
2022
Received:
June 16,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Inc. All rights reserved.
